16592-8 |
Chlamydia sp Ab.IgM |
ACnc |
CSF |
Pt |
Qn |
IF |
|
ACTIVE |
Chlamydia sp IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16592-8 |
|
IF |
|
|
Both |
|
|
|
0 |
Chlamydia IgM CSF IF-aCnc |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Chlam; Chlamid; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; species; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; spp; Time Resolved Fluorescence; TRF |
2.73 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16593-6 |
Chlamydia sp Ag |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Chlamydia sp Ag [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16593-6 |
|
|
|
|
Both |
|
|
|
0 |
Chlamydia Ag Ur Ql |
|
|
|
|
|
Antigen; Antigens; Chlam; Chlamid; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; spp; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16594-4 |
Chlamydia trachomatis Ab.IgA |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Chlamydia trachomatis IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
16594-4 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach IgA Titr CSF IF |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; C trac; C trach; C tracho; C trachomatis; Cerebral spinal fluid; Cerebrospinal Fl; Chlam; Chlam trac; Chlamid; CT; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin A; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin A; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; Trachoma; TRF; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
16595-1 |
Chlamydia trachomatis Ab.IgG |
ACnc |
CSF |
Pt |
Qn |
IF |
|
ACTIVE |
Chlamydia trachomatis IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16595-1 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach IgG CSF IF-aCnc |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; C trac; C trach; C tracho; C trachomatis; Cerebral spinal fluid; Cerebrospinal Fl; Chlam; Chlam trac; Chlamid; CT; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Trachoma; TRF |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16596-9 |
Chlamydia trachomatis Ab.IgM |
ACnc |
CSF |
Pt |
Qn |
IF |
|
ACTIVE |
Chlamydia trachomatis IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16596-9 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach IgM CSF IF-aCnc |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; C trac; C trach; C tracho; C trachomatis; Cerebral spinal fluid; Cerebrospinal Fl; Chlam; Chlam trac; Chlamid; CT; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Trachoma; TRF |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16597-7 |
Chlamydia trachomatis B Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Chlamydia trachomatis B IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16597-7 |
|
|
|
|
Both |
|
|
|
0 |
C trach B IgG Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; C trac; C trach; C trach B; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; Chlamydia trachomatis type B; CT; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Trachoma |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16598-5 |
Chlamydia trachomatis C Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Chlamydia trachomatis C IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16598-5 |
|
|
|
|
Both |
|
|
|
0 |
C trach C IgG Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; C trac; C trach; C trach C; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; Chlamydia trachomatis type C; CT; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Rh Blood Group System; Serum; SR; Trachoma |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16599-3 |
Chlamydia trachomatis DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Chlamydia trachomatis DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16599-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C trach DNA Bld Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Trachoma; Transcription mediated amplification; WB; Whole blood |
2.63 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
166-9 |
Cephapirin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cephapirin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
166-9 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Cephapirin Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefadyl; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1660-0 |
11-Hydroxyetiocholanolone |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
11-Hydroxyetiocholanolone [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
1660-0 |
|
|
|
|
Both |
|
|
|
0 |
11OH-Etioch Ser-mCnc |
|
|
|
Y |
|
11 beta-hydroxyandrosterone; 11-Hydroxy etiocholanolone; 11OH-Etioch; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
1 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
16600-9 |
Chlamydia trachomatis rRNA |
PrThr |
Genital |
Pt |
Ord |
Probe |
|
ACTIVE |
Chlamydia trachomatis rRNA [Presence] in Genital specimen by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16600-9 |
|
Probe |
|
|
Both |
|
|
|
0 |
C trach rRNA Genital Ql Probe |
|
|
|
|
|
C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; DNA NUCLEIC ACID PROBE; DNA probe; Gen; Genital tract; ID; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; Trachoma; Urogenit; Urogenital |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16601-7 |
Chlamydia trachomatis rRNA |
PrThr |
Urine |
Pt |
Ord |
Probe |
|
DISCOURAGED |
Chlamydia trachomatis rRNA [Presence] in Urine by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16601-7 |
|
Probe |
|
|
Both |
|
|
|
0 |
C trach rRNA Ur Ql Probe |
|
|
|
|
|
C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; Trachoma; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16602-5 |
Chlamydia trachomatis rRNA |
ACnc |
Urine |
Pt |
Ord |
Probe |
|
DEPRECATED |
Deprecated Chlamydia trachomatis rRNA [Presence] in Urine by DNA probe |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16602-5 |
|
Probe |
|
|
Both |
|
|
|
0 |
Deprecated C trach rRNA Ur Ql Prb |
|
|
|
|
|
Arbitrary concentration; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Ordinal; Point in time; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; Trachoma; UA; UR; Urn |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16603-3 |
Chloramphenicol^peak |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chloramphenicol [Mass/volume] in Serum or Plasma --peak |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
16603-3 |
|
|
|
|
Both |
|
|
|
0 |
Chloramphen Peak SerPl-mCnc |
|
|
|
Y |
|
Amphicol; Biophenicol; c225; Chloramphen; Chloromycetin; DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Mass concentration; Mychel; Paraxin; Pl; Plasma; Plsm; Point in time; Post; Postdose; Post-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
16604-1 |
Chloramphenicol^trough |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chloramphenicol [Mass/volume] in Serum or Plasma --trough |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
16604-1 |
|
|
|
|
Both |
|
|
|
0 |
Chloramphen Trough SerPl-mCnc |
|
|
|
Y |
|
Amphicol; Biophenicol; c225; Chloramphen; Chloromycetin; DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Mass concentration; Mychel; Paraxin; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
16605-8 |
Chlorocycline |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Chlorocycline [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16605-8 |
|
|
|
|
Both |
|
|
|
0 |
Chlorocycline Ur-mCnc |
|
|
|
Y |
|
Chlorcyclizine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16606-6 |
Chlorine |
MCnc |
Dial fld |
Pt |
Qn |
|
|
ACTIVE |
Chlorine [Mass/volume] in Dialysis fluid |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
16606-6 |
|
|
|
|
Both |
|
|
|
0 |
Chlorine Dial fld-mCnc |
|
|
|
Y |
|
Cl2; Diaf; Dialysate; Dialysis fluid; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.44 |
1.0l |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
16607-4 |
Chlorine |
MCnc |
Water |
Pt |
Qn |
|
|
ACTIVE |
Chlorine [Mass/volume] in Water |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16607-4 |
|
|
|
|
Observation |
|
|
|
0 |
Chlorine Wat-mCnc |
|
|
|
Y |
|
Cl2; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Wat |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16608-2 |
Chlorpheniramine |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Chlorpheniramine [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16608-2 |
|
|
|
|
Both |
|
|
|
0 |
Chlorphenir Ur-aCnc |
|
|
|
Y |
|
Arbitrary concentration; CHL; Chlorphenamine; Chlorphenir; Chlortrimeton; Chlor-tripolon; DRUG/TOXICOLOGY; Drugs; Piriton; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16609-0 |
Chlorphentermine |
ACnc |
Bld |
Pt |
Qn |
|
|
DISCOURAGED |
Chlorphentermine [Units/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16609-0 |
|
|
|
|
Both |
|
|
|
0 |
Chlorphentermin Bld-aCnc |
|
|
|
Y |
|
Addiction; Arbitrary Concentration; Blood; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Lucofen; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
1661-8 |
11-Ketoandrosterone |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
11-Ketoandrosterone [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
1661-8 |
|
|
|
|
Both |
|
|
|
0 |
11Ketoandros Ser-mCnc |
|
|
|
Y |
|
11Ketoandros; Chemistry; Ketoandrost; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
16610-8 |
Chlorphentermine |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Chlorphentermine [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16610-8 |
|
|
|
|
Both |
|
|
|
0 |
Chlorphentermin Ur-aCnc |
|
|
|
Y |
|
Addiction; Arbitrary Concentration; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Lucofen; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16611-6 |
Chlorpyrifos |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Chlorpyrifos [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16611-6 |
|
|
|
|
Both |
|
|
|
0 |
Chlorpyrifos Ur-mCnc |
|
|
|
Y |
|
Brodan; Detmol UA; Dowco 179; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16612-4 |
Chlorthalidone |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chlorthalidone [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16612-4 |
|
|
|
|
Both |
|
|
|
0 |
Chlorthalidone SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Hygroton; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thalitone |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
16613-2 |
Cholesterol crystals |
PrThr |
Calculus |
Pt |
Ord |
Infrared spectroscopy |
|
ACTIVE |
Cholesterol crystals [Presence] in Stone by Infrared spectroscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16613-2 |
|
Infrared spectroscopy |
|
|
Observation |
|
|
|
0 |
Cholest Cry Stone Ql IR |
|
|
|
|
|
Calc; Calculi; Chemistry; Chol; Choles; Cholest; Cholest Cry; Cholesterol total; Cholesterols; Crys; Cryst; Crystal; Gastro; Gastroenterology; GI; Infared spectoscopy; IR; Kidney; Lipid; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; Stn; Stone; Stones |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |